5.2 Intracranial Hemorrhage & Elevated ICP Pharmacotherapy

5.2 Intracranial Hemorrhage & Elevated ICP Pharmacotherapy

Intracranial hemorrhage encompasses spontaneous intracerebral hemorrhage (sICH) and aneurysmal subarachnoid hemorrhage (aSAH), both carrying high morbidity and mortality. Unlike acute ischemic stroke where the core goal is reperfusion, the emergency pharmacotherapy of acute intracranial hemorrhage focuses on immediate hemostasis, preventing hematoma expansion, averting secondary rebleeding, preserving cerebral perfusion pressure, and rapidly mitigating elevated intracranial pressure (ICP).

---

Spontaneous Intracerebral Hemorrhage (sICH): Hemodynamic Control

Spontaneous intracerebral hemorrhage is most frequently caused by rupture of small penetrating arterioles damaged by chronic hypertension (lipohyalinosis) or cerebral amyloid angiopathy (CAA). Approximately 30% to 38% of patients experience significant hematoma expansion within the first few hours after symptom onset. Early hematoma growth directly correlates with neurological deterioration, permanent disability, and 30-day mortality. Acute, extreme blood pressure elevation is the predominant modifiable driver of hematoma expansion.

Landmark Clinical Trials: INTERACT-2 and ATACH-2

The optimal blood pressure target in acute sICH was defined through two major international randomized controlled trials:

1. INTERACT-2 Trial (2013): Randomly assigned 2,839 sICH patients presenting within 6 hours with SBP between 150 and 220 mmHg to intensive blood pressure lowering (target SBP $<140\text{ mmHg}$ within 1 hour) versus standard guideline-based lowering (target SBP $<180\text{ mmHg}$). The primary outcome (death or major disability) narrowly missed significance (OR 0.87, p=0.06), but the ordinal analysis showed a favorable shift in modified Rankin Scale scores at 90 days (OR 0.87, p=0.04) without increasing mortality or serious adverse events.
2. ATACH-2 Trial (2016): Evaluated 1,000 sICH patients presenting within 4.5 hours randomized to intensive reduction (target SBP 110 to 139 mmHg) versus standard reduction (target SBP 140 to 179 mmHg) using intravenous nicardipine. The trial was halted prematurely for futility: the intensive group showed no significant reduction in death or severe disability at 90 days compared to the standard group. Crucially, the intensive arm experienced a significantly higher rate of renal adverse events within 7 days (9.0% vs. 4.0%, p=0.002) and an increased incidence of cardiac adverse events.

Contemporary Guideline Consensus (AHA/ASA 2022 Guidelines)

• Target Blood Pressure: In mild-to-moderate ICH with SBP between 150 and 220 mmHg, acute lowering to a target SBP of 140 mmHg, maintained in the 130 to 150 mmHg range, is safe and may improve functional outcome (Class 2b). Start treatment within 2 hours of presentation and reach the target within about 1 hour.
• The Lower Floor: Lowering SBP below 130 mmHg in these patients is potentially harmful (Class 3: Harm), consistent with ATACH-2's renal adverse events.
• Large or Severe Hemorrhage: The benefit of intensive lowering is not established for large hematomas or patients needing surgical decompression.
• Pharmacologic Selection: Continuous intravenous infusions of nicardipine (5 to 15 mg/h) or clevidipine (1 to 32 mg/h) are preferred over intermittent IV boluses. Continuous infusions minimize blood pressure variability; large systolic fluctuations are independently associated with hematoma expansion and poor neurologic recovery.

---

Aneurysmal Subarachnoid Hemorrhage (aSAH) Pharmacotherapy

Aneurysmal subarachnoid hemorrhage, most commonly resulting from the rupture of an intracranial saccular "berry" aneurysm, presents with a sudden, catastrophic "thunderclap" headache. Medical management focuses on two distinct phases: preventing pre-securement aneurysm rebleeding, and preventing delayed cerebral ischemia (DCI).

1. Pre-Securement Blood Pressure Management

Prior to surgical clipping or endovascular coiling of the ruptured aneurysm, the unsecured vascular pouch is under extreme transmural stress. A sudden blood pressure surge can trigger fatal aneurysm rebleeding (which carries an 80% mortality rate). However, excessive hypotension reduces cerebral perfusion pressure, causing ischemic stroke.

• Guideline Blood Pressure Target: Maintain SBP $<160\text{ mmHg}$ (or mean arterial pressure [MAP] $<110\text{ mmHg}$) using titratable IV infusions (nicardipine, clevidipine, or labetalol) prior to aneurysm securing.
• Once the aneurysm is definitively secured by clipping or coiling, blood pressure targets are relaxed; induced permissive hypertension is utilized if delayed cerebral ischemia develops.

2. Neuroprotection & Vasospasm Prevention: Nimodipine

Delayed cerebral ischemia (DCI) typically develops between day 4 and day 14 post-bleed (peaking at days 7 to 10). Historically attributed solely to large-vessel macrovascular vasospasm visible on angiography, contemporary evidence demonstrates that DCI is primarily driven by microvascular spasm, microthrombosis, cortical spreading depolarization, and calcium-dependent apoptotic neuronal cell death.

• Pharmacologic Agent of Choice: Nimodipine.
• Mechanism: Highly lipophilic dihydropyridine calcium channel blocker that readily crosses the blood-brain barrier. Nimodipine does not significantly reverse or prevent macroscopic large-vessel vasospasm on catheter angiography; rather, it provides profound neuroprotection by preventing intracellular calcium overload in ischemic neurons and stabilizing microvascular tone.
• Dosing & Duration: 60 mg orally (or via nasogastric/orogastric tube) every 4 hours for 21 consecutive days, initiated within 96 hours of symptom onset.

• Managing Nimodipine-Induced Hypotension: If SBP drops below 90 to 100 mmHg during nimodipine therapy, do NOT permanently discontinue the drug. Instead, adjust the dosing interval to 30 mg orally every 2 hours, administer isotonic intravenous crystalloids to support intravascular volume, or co-administer a low-dose vasopressor (norepinephrine) to maintain perfusion while preserving the 21-day neuroprotective course.

---

Osmotherapy for Intracranial Hypertension & Cerebral Edema

Intracranial pressure (ICP) dynamics are governed by the Monro-Kellie Doctrine, which dictates that the rigid cranial vault has a fixed total volume occupied by three non-compressible components: brain parenchyma (80%), blood (10%), and cerebrospinal fluid (10%):

$V_{intracranial} = V_{brain} + V_{blood} + V_{CSF} = \text{Constant}$

When a mass lesion, hematoma, or severe cytotoxic/vasogenic edema expands one compartment, compensatory displacement of venous blood and CSF occurs. Once these spatial compensatory mechanisms are exhausted, intracranial pressure rises exponentially. Normal ICP is 5 to 15 mmHg; sustained elevations $>20\text{ to }22\text{ mmHg}$ require immediate emergency intervention to maintain Cerebral Perfusion Pressure (CPP):

$CPP = MAP - ICP \quad (\text{Clinical Goal: } 60\text{ to }70\text{ mmHg})$

Loading diagram...

1. Hypertonic Saline (HTS)

Hypertonic sodium chloride solutions create an osmotic gradient across an intact blood-brain barrier, drawing free water from the intracellular and interstitial compartments of brain tissue into the intravascular space, rapidly decreasing brain tissue volume and ICP.

• 3% Hypertonic Saline (Osmolarity: 1,026 mOsm/L; 513 mEq/L Na+):

  • Dosing: 250 to 500 mL IV bolus administered over 15 to 30 minutes, or continuous infusion titrated to target serum sodium.
  • Laboratory Targets: Target serum sodium 145 to 155 mEq/L; target serum osmolarity $<320\text{ mOsm/L}$.
  • Clinical Advantages: Preserves and expands intravascular volume, increases cardiac output, and supports blood pressure. Preferred osmotherapy in hypotensive neurotrauma or polytrauma patients.
  • Complications: Hyperchloremic metabolic acidosis (chloride load drives renal bicarbonate excretion), hypokalemia, and volume overload. If chronic hyponatremia is present, rapid sodium overcorrection can precipitate fatal osmotic demyelination syndrome (central pontine myelinolysis).

• 23.4% Sodium Chloride ("Salt Bomb" / Super-Hypertonic Saline; Osmolarity: ~8,008 mOsm/L; 4 mEq/mL Na+):

  • Dosing: 30 mL IV bolus administered over 10 to 15 minutes.
  • Clinical Indication: Emergent rescue therapy for impending cerebral herniation (unilateral blown pupil, decerebrate posturing, or Cushing's triad: hypertension, bradycardia, irregular breathing).
  • Vascular Access Mandate: Strictly requires a Central Venous Catheter (CVC) due to severe chemical thrombophlebitis and catastrophic skin necrosis if peripheral extravasation occurs (can be given through a large, dedicated proximal peripheral IV only in an extreme, cardiac-arrest-adjacent crisis while CVC is established).

2. 20% Mannitol

Mannitol is an impermeant hexahydroxy sugar alcohol that acts as an osmotic diuretic.

• Dosing: 0.5 to 1 g/kg IV (20% solution provides 20 g / 100 mL; typical adult dose 50 to 100 g) administered over 20 to 30 minutes.
• Dual Mechanism:
  1. Rheologic Effect (Immediate, 1 to 5 min): Decreases blood viscosity, expands intravascular volume, and causes reflex cerebral vasoconstriction while maintaining cerebral oxygen delivery.
  2. Osmotic Effect (Delayed, 15 to 30 min): Establishes a transmembrane osmotic gradient drawing water from the brain parenchyma into the vascular compartment for renal excretion.
• Administration Requirement: Must be infused through an in-line filter (0.22 or 5 micron). Mannitol crystallizes readily at room temperature; crystallized vials must be inspected and warmed to redissolve crystals prior to infusion.
• Complications & Contraindications:
  • Induces profound osmotic diuresis, leading to severe hypovolemia, hypotension, and prerenal azotemia.
  • Contraindications: Systolic blood pressure $<90\text{ mmHg}$ or active shock, anuria, severe renal failure, and pulmonary edema/severe congestive heart failure (initial transient intravascular expansion exacerbates pulmonary capillary hydrostatic pressure).
  • Monitoring: Check serum osmolarity and osmolar gap every 6 to 8 hours. Withhold mannitol if the osmolar gap exceeds 15 to 20 mOsm/kg or serum osmolarity exceeds 320 mOsm/kg due to acute tubular necrosis risk.

---

Osmotherapy Comparison Matrix